Gefitinib - Wikipedia

Gefitinib is an EGFR inhibitor, like erlotinib, which interrupts signaling through the epidermal growth factor receptor (EGFR) in target cells. Therefore, ...

Gefitinib - Wikipedia, den frie encyklopædi

Gefitinib (ZD1839) (handelsnavn:Iressa) er et lægemiddel, der anvendes til bestemte typer af bryst-og lungekræft samt en række andre cancertyper.

Gefitinib - National Cancer Institute - Comprehensive ...

This page contains brief information about gefitinib and a collection of links to more information about the use of this drug, research results, and ongoing clinical ...

Gefitinib - pro.medicin.dk – information om medicin

Pro.medicin.dk er en hjemmeside og database, der indeholder information om lægemidler og behandlingsvejledninger til læger, farmaceuter og andre ...

Iressa | European Medicines Agency

The active substance in Iressa, gefitinib, is a protein-tyrosine-kinase inhibitor. This means that it blocks specific enzymes known as tyrosine kinases.

Activating Mutations in the Epidermal Growth Factor ...

Background Most patients with non–small-cell lung cancer have no response to the tyrosine kinase inhibitor gefitinib, which targets the epidermal growth factor ...

Gefitinib | C22H24ClFN4O3 - PubChem - The PubChem Project

Gefitinib | C22H24ClFN4O3 | CID 123631 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities ...

Gefitinib: Indications, Side Effects, Warnings - Drugs.com

Easy-to-read patient leaflet for Gefitinib. Includes indications, proper use, special instructions, precautions, and possible side effects.

Iressa® - pro.medicin.dk – information om medicin

Ikke-småcellet lungecancer, som udtrykker EGFR. Gefitinib bør kun anvendes, når behandlingen forestås af læger med særligt kendskab til maligne lidelser og ...

Gefitinib.

Based on this study gefitinib was approved for the first-line treatment of the patients with non-small cell lung cancer (NSCLC) with sensitising EGFR mutations ...